Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)
Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)
The study is designed as a Phase II, multicenter trial of vaccination with Dendritic
 cell/myeloma fusions with granulocyte macrophage colony-stimulating factor (GM-CSF) adjuvant
 plus lenalidomide maintenance therapy versus maintenance therapy alone or with GM-CSF
 following autologous transplant as part of upfront treatment of multiple myeloma (MM). It is
 hypothesized that the dendritic cell myeloma vaccine will result in improved response in
 patients with multiple myeloma after autologous Hematopoietic Cell Transplant (HCT).
The study is a three-arm, phase II randomized, open-labeled clinical trial that randomizes
 patients to vaccination with Dendritic Cell (DC)/myeloma fusions/GM-CSF plus lenalidomide
 maintenance therapy or lenalidomide maintenance therapy with or without GM-CSF following
 autologous transplant as part of upfront treatment for patients diagnosed with multiple
 myeloma. Patients are randomized approximately 2 months post transplant and will begin
 maintenance lenalidomide between day 90 and 100. The primary objective of this randomized
 trial is to compare the proportion of patients alive and in complete response (defined as CR
 or sCR) at one year post transplant between patients receiving DC/myeloma vaccine/GM-CSF with
 lenalidomide maintenance therapy to those receiving lenalidomide maintenance therapy with or
 without GM-CSF.
Initial Inclusion Criteria:

 1. Patients must be considered transplant eligible by the treating physician at time of
 study entry.

 2. Patients must meet the criteria for symptomatic multiple myeloma prior to initiating
 systemic anti-myeloma treatment.

 3. Age >18 years and ≤ 70 years at the time of enrollment

 4. Karnofsky Performance status of ≥ 70%

 5. Patients must have > 20% plasma cells in the bone marrow aspirate differential <60
 days prior to enrollment. The required bone marrow evaluation will need to be repeated
 for patients who received more than 1 cycle of anti-myeloma therapy (corticosteroid
 with or without other anti-myeloma agents)

 6. Patients must have received ≤ 1 cycles of systemic anti-myeloma therapy.

 7. Renal: Creatinine clearance of ≥ 40 mL/min, estimated or calculated.

 Initial Exclusion Criteria:

 1. Patients with a prior autologous or allogeneic HCT

 2. Patients with purely non-secretory MM [absence of a monoclonal protein (M protein) in
 serum as measured by electrophoresis and immunofixation and the absence of Bence Jones
 protein in the urine defined by use of conventional electrophoresis and immunofixation
 techniques and the absence of involved serum free light chain >100 mg/L]. Patients
 with light chain MM detected in the serum by free light chain assay are eligible.

 3. Patients with Plasma Cell Leukemia

 4. Patients with disease progression prior to enrollment

 5. Patients seropositive for the human immunodeficiency virus (HIV).

 6. Myocardial infarction within 6 months prior to enrollment or New York Heart
 Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe
 uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute
 ischemia or active conduction system abnormalities. Prior to study entry, any ECG
 abnormality at screening will be documented by the investigator as not medically
 relevant.

 7. Patients with active clinically significant autoimmune disease, defined as a history
 of requiring systemic immunosuppressive therapy and at ongoing risk for potential
 disease exacerbation. Patients with a history of autoimmune thyroid disease, asthma,
 or limited skin manifestations are potentially eligible.

 8. Patients receiving other investigational immunotherapy or anti-myeloma drugs within 14
 days before enrollment.

 9. Patients with prior malignancies except resected basal cell carcinoma or treated
 cervical carcinoma in situ. Cancer treated with curative intent < 5 years prior to
 enrollment will not be allowed unless approved by the Protocol Officer or one of the
 Protocol Chairs. Cancer treated with curative intent > 5 years prior to enrollment is
 allowed.

 10. Female patients who are pregnant (positive beta-HCG) or breastfeeding.

 11. Females of childbearing potential (FCBP) or men who have sexual contact with FCBP
 unwilling to use contraceptive techniques (Appendix D) during the length of
 lenalidomide maintenance therapy.

 12. Patients who have received mid-intensity melphalan (>50 mg IV) as part of prior
 therapy.

 13. Prior organ transplant requiring immunosuppressive therapy.

 14. Patients who previously received lenalidomide and have experienced toxicities
 resulting in treatment discontinuation.

 15. Patients who experienced thromboembolic events while on full anticoagulation during
 prior therapy with lenalidomide or thalidomide.

 16. Patients unwilling to take deep vein thrombosis (DVT) prophylaxis.

 17. Patients unable or unwilling to provide informed consent.

 18. Patients unable or unwilling to return to the transplant center for their assigned
 treatments.

 Randomization Inclusion Criteria:

 1. Patient received transplant < 12 months of enrollment onto BMT CTN 1401.

 2. No disease progression since initiation of systemic anti-myeloma therapy as determined
 within seven days of randomization/enrollment.

 3. Received an autologous cell transplant with melphalan 200mg/m^2 with a minimum cell
 dose of 2x10^6 CD34+ cells/kg (actual body weight).

 4. Mucositis and gastrointestinal symptoms resolved, off hyperalimentation and
 intravenous hydration.

 5. No evidence of uncontrolled infection requiring systemic therapy. Patients who
 completed treatment for an infection but are continuing antibiotics, anti-viral, or
 anti-fungal therapy for prophylaxis are eligible to continue on protocol.

 6. Platelet count ≥75,000/mm^3 (without transfusion in previous 7 days).

 7. Absolute neutrophil count (ANC) ≥ 1,500/mm^3 without filgrastim administration within
 7 days, or pegfilgrastim within 14 days of measurement.

 8. Hepatic: bilirubin < 2x the upper limit of normal and alanine aminotransferase (ALT)
 and aspartate aminotransferase (AST) < 2.5x the upper limit of normal. (Patients who
 have been diagnosed with Gilbert's Disease are allowed to exceed the defined bilirubin
 value of 2x the upper limit of normal)

 9. Renal: Creatinine clearance of ≥ 40 mL/min, estimated or calculated. Patients with
 creatinine clearance ≥30 but <40 will be considered with review/approval from the
 protocol chairs or officer if the cause of renal insufficiency is associated with
 multiple myeloma.

 10. All study participants must be registered into the mandatory Revlimid REMs program,
 and be willing and able to comply with the requirements.

 11. Females of childbearing potential (FCBP) as defined in section 2.7.1.1 must have a
 negative serum pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14
 days prior to and again within 24 hours of prescribing lenalidomide (prescriptions
 must be filled within 7 days)

 12. FCBP must either commit to abstain continuously from sexual intercourse or use TWO
 acceptable methods of birth control, one highly effective method and one additional
 effective method AT THE SAME TIME, at least 4 weeks before she starts taking
 lenalidomide, during therapy, during dose interruptions, and continuing for 4 weeks
 following discontinuation of lenalidomide.

 13. FCBP must agree to ongoing pregnancy testing as required by the Revlimid REMs program.

 14. Men must agree to use a latex condom during sexual contact with females of child
 bearing potential even if they have had a successful vasectomy while taking
 lenalidomide, during dose interruptions and for 28 days after discontinuing
 lenalidomide.

 15. Patients must be willing to receive DVT prophylaxis.